These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22988880)

  • 1. LRRK2 and autophagy: a common pathway for disease.
    Manzoni C
    Biochem Soc Trans; 2012 Oct; 40(5):1147-51. PubMed ID: 22988880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
    Xiong Y; Dawson VL; Dawson TM
    Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cell Biology of LRRK2 in Parkinson's Disease.
    Usmani A; Shavarebi F; Hiniker A
    Mol Cell Biol; 2021 Apr; 41(5):. PubMed ID: 33526455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
    Seol W
    BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible involvement of the relationship of LRRK2 and autophagy in Parkinson's disease.
    Bravo-San Pedro JM; Gómez-Sánchez R; Niso-Santano M; Pizarro-Estrella E; González-Polo RA; Fuentes JM
    Biochem Soc Trans; 2012 Oct; 40(5):1129-33. PubMed ID: 22988877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering the function of leucine-rich repeat kinase 2 and targeting its dysfunction in disease.
    Lewis PA; Alessi DR
    Biochem Soc Trans; 2012 Oct; 40(5):1039-41. PubMed ID: 22988861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 in Parkinson's disease: biochemical functions.
    Anand VS; Braithwaite SP
    FEBS J; 2009 Nov; 276(22):6428-35. PubMed ID: 19804416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for Parkinson's disease-linked LRRK2's binding to microtubules.
    Snead DM; Matyszewski M; Dickey AM; Lin YX; Leschziner AE; Reck-Peterson SL
    Nat Struct Mol Biol; 2022 Dec; 29(12):1196-1207. PubMed ID: 36510024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
    Gandhi PN; Chen SG; Wilson-Delfosse AL
    J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
    Tsika E; Moore DJ
    Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A link between LRRK2, autophagy and NAADP-mediated endolysosomal calcium signalling.
    Gómez-Suaga P; Churchill GC; Patel S; Hilfiker S
    Biochem Soc Trans; 2012 Oct; 40(5):1140-6. PubMed ID: 22988879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
    Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
    Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An emerging role for LRRK2 in the immune system.
    Dzamko N; Halliday GM
    Biochem Soc Trans; 2012 Oct; 40(5):1134-9. PubMed ID: 22988878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 and human disease: a complicated question or a question of complexes?
    Lewis PA; Manzoni C
    Sci Signal; 2012 Jan; 5(207):pe2. PubMed ID: 22253261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond.
    Bae JR; Lee BD
    BMB Rep; 2015 May; 48(5):243-8. PubMed ID: 25703537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional variants in the
    Hui KY; Fernandez-Hernandez H; Hu J; Schaffner A; Pankratz N; Hsu NY; Chuang LS; Carmi S; Villaverde N; Li X; Rivas M; Levine AP; Bao X; Labrias PR; Haritunians T; Ruane D; Gettler K; Chen E; Li D; Schiff ER; Pontikos N; Barzilai N; Brant SR; Bressman S; Cheifetz AS; Clark LN; Daly MJ; Desnick RJ; Duerr RH; Katz S; Lencz T; Myers RH; Ostrer H; Ozelius L; Payami H; Peter Y; Rioux JD; Segal AW; Scott WK; Silverberg MS; Vance JM; Ubarretxena-Belandia I; Foroud T; Atzmon G; Pe'er I; Ioannou Y; McGovern DPB; Yue Z; Schadt EE; Cho JH; Peter I
    Sci Transl Med; 2018 Jan; 10(423):. PubMed ID: 29321258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
    Greggio E
    Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
    Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
    Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 in Parkinson's disease: function in cells and neurodegeneration.
    Webber PJ; West AB
    FEBS J; 2009 Nov; 276(22):6436-44. PubMed ID: 19804415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.